You can buy or sell NTLA and other stocks, options, ETFs, and crypto commission-free!
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. Read More The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Simply Wall StMar 12
If You Had Bought Intellia Therapeutics (NASDAQ:NTLA) Stock A Year Ago, You’d Be Sitting On A 50% Loss, Today
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders should be happy to see the share price up 23% in the last month. But that’s not enough to compensate for the decline over the last twelve months. Like a receding glacier in a warming world, the share price has melted 50% in that period. The share price recovery is not so impressive when you consider the fall. Of course, it could be that the fall was overdone. See our latest analysis for Intellia Therapeutics Intellia Therapeutics isn’t a profitable co...
Stock Price, News, & Analysis for Intellia Therapeutics
News coverage about NTLA stock has trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Intellia Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of ...
Yahoo FinanceMar 1
Intellia CEO not involved in Starboard's Bristol-Myers board challenge
FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau/File Photo By Greg Roumeliotis NEW YORK (Reuters) - Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday. "He is not...
Expected Apr 30, Pre-Market